Thursday, October 6, 2011
Four small and mid-sized clinical research service companies—Averion International, Trio Clinical Research, Fulcrum Pharma and Clin-Research/ADDPLAN—have merged into one global biopharmaceutical and medical device development services organization that will focus on niche areas, including adaptive trials and new technologies, which can help sponsors make decisions about their drug candidates faster.
Full-year 2008 revenues for oncology CRO Averion increased 90% over 2007, thanks in large part to an increase in European activity and the October 2007 acquisition of Hesperion, a clinical research organization based in Switzerland. Net service revenues in 2008 were $66.4 million, compared with $34.9 million in 2007.
Just a day after releasing disappointing third quarter results, Morrisville, N.C.-based eClinical company etrials named a new president and CEO, M. Denis Connaghan, replacing interim president and CEO Chuck Piccirillo. Piccirillo, who will resume his position as vice president of technology, has served as interim CEO since the resignation of Eugene “Chip” Jennings in July. Connaghan was formerly managing director within Marsh USA’s Global Operations.
Averion International, an international contract research organization (CRO) specializing in oncology and cardiovascular diseases, appointed Peter Gonze executive vice president of global business development, a role that will focus on increasing Averion’s business efforts in international markets.
Adding yet another key Eastern European country to its footprint in the region, Southborough,Mass.-based contract research organization (CRO) Averion has opened an office in Kiev, Ukraine—the country’s capital and largest city. The office is being led by Evgeny Levenko, M.D., PhD, Averion’s affiliate manager for Ukraine.